undamentalytics Newsletter
Sign in

Sarepta Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Sarepta Therapeutics, Inc. had total assets of $3.35bn, total liabilities of $2.21bn and shareholders' equity of $1.14bn. It held $801m in cash against $829m of debt: net debt of $27.7m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents74801226003718351,5032,1169674281,103801571
Receivables245294991101153215400602398377
Inventory——1384125171232186204323750915904
Total current assets2482253731,2291,4261,4692,4852,6042,5582,5793,0732,5382,224
Total assets2952744241,3081,6421,8232,9853,1483,1283,2653,9633,3503,189
Accounts payable12203083468111779616521428151
Deferred revenue (current)33333389898950130443110
Total current liabilities376275881742654164536206547321,095503
Short-term debt0———————01050——
Long-term debt12718431421——5641,5441,2381,137829848
Total debt102918431421—05641,5441,2381,137829848
Total liabilities4783875196101,0052,2232,2202,7432,4052,4352,2091,661
Shareholders' equity2481903377891,0328187629283858591,5281,1411,528
Net debt (negative = net cash)−64−51−105−16950−835−1,503−1,5525788103428276
Shares outstanding41m46m55m65m71m75m79m87m88m94m97m105m106m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: MRNA vs SRPTALKS vs SRPTHALO vs SRPT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Sarepta Therapeutics, Inc.